Rnt Medical College, Bhilwara, Udaipur.
J Assoc Physicians India. 2022 Apr;70(4):11-12.
The coronavirus disease 2019 (COVID-19) virus has spread all over the world. Scientists are trying to discover drugs as effective treatment for patients with COVID-19. So far about 30 drugs have been introduced that one of them is Tocilizumab. Some reports showed a positive effect of Tocilizumab on Saturation of Peripheral Oxygen (SPO2) but results of CT scan in patients in different. In some patients, CT scan showed reduced infiltration, however in other no change was observed. Unfortunately, until now there has been no definitive and effective treatment for patients with COVID-19. Based on evidence of the Tocilizumab's effect on the SARS COV 2, researchers hope this drug will make effective and promising treatment to improve lung tissue inflammation in patients with the fatal COVID-19 virus. The present study provides an overview of respiratory inflammation with COVID-19 and probable effect of Tocilizumab on SARS-COV 2.
A Case Series was conducted on 30 patients, RT-PCR confirmed COVID-19 cases; admitted and kept under observation in medicine ward, ICU or dedicated COVID-19 wards of RNT Medical College and associated group of Hospitals for a duration of 30 days after getting approval from institutional ethics committee if they met inclusion and exclusion criteria. Data was collected from records at the time of admission of these cases.
In our study on day 1 mean of IL6 was 248.3 and on day 3 after giving injection Tocilizumab mean of IL6 was 138.7 and p value was 0.205 and on day1 mean of serum ferritin was 474.2 and on day 3 after giving injection Tocilizumab mean of serum ferritin was 415.2 and p value was 0.649 and on day 1 mean of LDH was 652 and on day 3 after giving injection Tocilizumab mean of LDH was 389.6 and p value was 0.006 and on day 1 mean of CRP was 100 and on day 3 after giving injection Tocilizumab mean of CRP was 35.95 and p value was 0.006 and out of 30 patient 22 patients were discharged and 8 patients declared death.
In present study it was interpreted that injection Tocilizumab play an important role in reducing inflammation in COVID 19disease. Tocilizumab have significant role in reducing mortality from COVID 19.
研究托珠单抗对 COVID-19 患者的疗效。
对 30 名 COVID-19 患者进行了回顾性研究，这些患者均接受了 RT-PCR 检测，被确诊为 COVID-19 病例。他们被收入 RNT 医学院及其附属医院的内科病房、重症监护室或专门的 COVID-19 病房进行观察，观察期为 30 天。在获得机构伦理委员会的批准后，我们收集了这些患者入院时的记录数据。
在第 1 天，IL-6 的平均值为 248.3，在第 3 天接受托珠单抗注射后，IL-6 的平均值为 138.7，p 值为 0.205。在第 1 天，血清铁蛋白的平均值为 474.2，在第 3 天接受托珠单抗注射后，血清铁蛋白的平均值为 415.2，p 值为 0.649。在第 1 天，LDH 的平均值为 652，在第 3 天接受托珠单抗注射后，LDH 的平均值为 389.6，p 值为 0.006。在第 1 天，CRP 的平均值为 100，在第 3 天接受托珠单抗注射后，CRP 的平均值为 35.95，p 值为 0.006。在这 30 名患者中，有 22 名患者出院，8 名患者死亡。
托珠单抗在 COVID-19 患者的治疗中发挥了重要作用，可以减轻炎症反应，降低死亡率。
